EW Edwards Lifesciences Corp

NYSE edwards.com


$ 73.35 $ 0.41 (0.56 %)    

Tuesday, 14-Oct-2025 15:59:59 EDT
QQQ $ 598.96 $ -4.01 (-0.67 %)
DIA $ 463.09 $ 2.03 (0.44 %)
SPY $ 662.74 $ -0.81 (-0.12 %)
TLT $ 90.60 $ 0.29 (0.32 %)
GLD $ 382.40 $ 2.70 (0.71 %)
$ 73.36
$ 72.95
$ 73.00 x 1
$ 74.00 x 10
$ 72.47 - $ 73.52
$ 64.89 - $ 83.00
3,508,553
na
43.07B
$ 1.04
$ 10.38
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2025 06-30-2025 10-Q
2 05-06-2025 03-31-2025 10-Q
3 02-28-2025 12-31-2024 10-K
4 11-06-2024 09-30-2024 10-Q
5 07-31-2024 06-30-2024 10-Q
6 04-29-2024 03-31-2024 10-Q
7 02-12-2024 12-31-2023 10-K
8 10-27-2023 09-30-2023 10-Q
9 07-28-2023 06-30-2023 10-Q
10 04-28-2023 03-31-2023 10-Q
11 02-13-2023 12-31-2022 10-K
12 10-28-2022 09-30-2022 10-Q
13 07-29-2022 06-30-2022 10-Q
14 04-28-2022 03-31-2022 10-Q
15 02-14-2022 12-31-2021 10-K
16 10-29-2021 09-30-2021 10-Q
17 07-30-2021 06-30-2021 10-Q
18 04-28-2021 03-31-2021 10-Q
19 02-12-2021 12-31-2020 10-K
20 10-26-2020 09-30-2020 10-Q
21 07-27-2020 06-30-2020 10-Q
22 04-28-2020 03-31-2020 10-Q
23 02-14-2020 12-31-2019 10-K
24 10-25-2019 09-30-2019 10-Q
25 07-26-2019 06-30-2019 10-Q
26 04-26-2019 03-31-2019 10-Q
27 02-15-2019 12-31-2018 10-K
28 10-26-2018 09-30-2018 10-Q
29 07-27-2018 06-30-2018 10-Q
30 04-27-2018 03-31-2018 10-Q
31 02-16-2018 12-31-2017 10-K
32 10-27-2017 09-30-2017 10-Q
33 07-28-2017 06-30-2017 10-Q
34 04-28-2017 03-31-2017 10-Q
35 02-17-2017 12-31-2016 10-K
36 10-28-2016 09-30-2016 10-Q
37 07-29-2016 06-30-2016 10-Q
38 04-29-2016 03-31-2016 10-Q
39 02-19-2016 12-31-2015 10-K
40 10-29-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 oppenheimer-downgrades-edwards-lifesciences-to-perform

Oppenheimer analyst Suraj Kalia downgrades Edwards Lifesciences (NYSE:EW) from Outperform to Perform.

 evercore-isi-group-upgrades-edwards-lifesciences-to-outperform-raises-price-target-to-88

Evercore ISI Group analyst Vijay Kumar upgrades Edwards Lifesciences (NYSE:EW) from In-Line to Outperform and raises the pri...

 heres-how-much-you-would-have-made-owning-edwards-lifesciences-stock-in-the-last-20-years

Edwards Lifesciences (NYSE: EW) has outperformed the market over the past 20 years by 7.57% on an annualized basis producing an...

 stifel-maintains-buy-on-edwards-lifesciences-lowers-price-target-to-85

Stifel analyst Rick Wise maintains Edwards Lifesciences (NYSE:EW) with a Buy and lowers the price target from $95 to $85.

 israel-englanders-millennium-goes-all-in-on-crypto-and-healthcare-while-rebalancing-big-tech-bets-bitcoin-etf-and-palantir-stakes-soar-in-q2

Millennium Management's Q2 2025 13F reveals big bets on crypto (IBIT, PLTR) & healthcare (EW, INSM), with tech rebalanc...

 deal-dispatch-performance-food-group-and-claires-lead-a-week-of-big-auctions-retail-woes

Performance Food rejects offer; Lufthansa drops Air Europa bid; NFL inks deal with ESPN; Claire's files bankruptcy amid ret...

 ftc-sounds-alarm-on-edwards-attempt-to-corner-heart-device-market

The FTC complaint alleges that if Edwards acquires JenaValve, it would gain control over the two most advanced TAVR-AR devices.

 wells-fargo-maintains-overweight-on-edwards-lifesciences-raises-price-target-to-88

Wells Fargo analyst Larry Biegelsen maintains Edwards Lifesciences (NYSE:EW) with a Overweight and raises the price target f...

 edwards-lifesciences-provides-comments-on-ftcs-action-to-block-proposed-acquisition-of-jenavalve-disagrees-with-ftcs-decision-and-believes-it-will-limit-the-availability-of-an-important-treatment-option-for-patients-suffering-from-aortic-regurgitation-intends-to-continue-to-pursue-regulatory-approval-of-the-acquisition-and-estimates-a-final-determination-by-the-end-of-q1-2026-increases-its-adjusted-eps-guidance-for-the-fy-to-the-high-end-of-245-255-up-from-the-high-end-of-240-250

Edwards Lifesciences (NYSE:EW) announced today that the U.S. Federal Trade Commission (FTC) moved to block the company's pr...

 edwards-lifesciences-stock-likely-to-see-sluggish-price-action-through-2027

Edwards Lifesciences may avoid bearishness but is likely to trade sluggishly through 2027, as key cycle phases signal limited u...

 jp-morgan-maintains-neutral-on-edwards-lifesciences-raises-price-target-to-85

JP Morgan analyst Robbie Marcus maintains Edwards Lifesciences (NYSE:EW) with a Neutral and raises the price target from $80...

 canaccord-genuity-maintains-hold-on-edwards-lifesciences-raises-price-target-to-81

Canaccord Genuity analyst William Plovanic maintains Edwards Lifesciences (NYSE:EW) with a Hold and raises the price target ...

 edwards-lifesciences-lifts-2025-outlook-on-strong-first-half-performance

Edwards Lifesciences beat Q2 estimates and raised its 2025 sales outlook as TAVR and TMTT segments drove double-digit revenue g...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION